Arrowstreet Capital
CPRX

Arrowstreet Capital’s Catalyst Pharmaceutical CPRX Stock Holding History

Arrowstreet Capital’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$23.7M Sell
955,315
-661,893
-41% -$15.8M 0.01% 705
2025
Q4 		$37.7M Buy
1,617,208
+312,434
+24% +$6.96M 0.02% 553
2025
Q3 		$25.7M Buy
1,304,774
+81,151
+7% +$1.67M 0.02% 657
2025
Q2 		$26.6M Buy
1,223,623
+188,594
+18% +$4.45M 0.02% 601
2025
Q1 		$25.1M Buy
1,035,029
+336,877
+48% +$7.59M 0.02% 535
2024
Q4 		$14.6M Buy
698,152
+396,506
+131% +$8.52M 0.01% 708
2024
Q3 		$6M Buy
+301,646
New +$5.59M 0.01% 908
2024
Q2 		– Sell
-12,921
Closed -$206K – 1553
2024
Q1 		$206K Buy
+12,921
New +$195K ﹤0.01% 1579
2023
Q4 		– Sell
-144,699
Closed -$1.69M – 1426
2023
Q3 		$1.69M Buy
144,699
+82,744
+134% +$1.11M ﹤0.01% 886
2023
Q2 		$833K Sell
61,955
-105,832
-63% -$1.52M ﹤0.01% 997
2023
Q1 		$2.78M Buy
+167,787
New +$2.77M ﹤0.01% 841
2022
Q3 		– Sell
-19,548
Closed -$137K – 1295
2022
Q2 		$137K Sell
19,548
-295,603
-94% -$2.17M ﹤0.01% 1181
2022
Q1 		$2.61M Buy
315,151
+139,102
+79% +$983K ﹤0.01% 749
2021
Q4 		$1.19M Buy
176,049
+145,249
+472% +$955K ﹤0.01% 1128
2021
Q3 		$163K Buy
+30,800
New +$168K ﹤0.01% 1522
2021
Q1 		– Sell
-295,292
Closed -$986K – 2282
2020
Q4 		$986K Buy
+295,292
New +$992K ﹤0.01% 1837
2020
Q3 		– Sell
-63,400
Closed -$293K – 2356
2020
Q2 		$293K Buy
+63,400
New +$285K ﹤0.01% 2110
2020
Q1 		– Sell
-731,259
Closed -$2.74M – 1902
2019
Q4 		$2.74M Buy
+731,259
New +$3.42M 0.01% 1042

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Arrowstreet Capital's CPRX Position: Q1 2026 in Review

Arrowstreet Capital reduced its Catalyst Pharmaceutical (CPRX) stake by 41% in Q1 2026, selling an estimated $15.8M and leaving 955,315 shares worth $23.7M. The position accounts for 0.01% of the portfolio, ranked #705.

Arrowstreet Capital first reported a position in CPRX in Q4 2019 and has held it in 18 quarters since. The position peaked at $37.7M in Q4 2025. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Arrowstreet Capital held 955,315 shares of Catalyst Pharmaceutical worth $23.7M as of Q1 2026.
  • Arrowstreet Capital sold 661,893 Catalyst Pharmaceutical shares in Q1 2026, an estimated $15.8M.
  • Catalyst Pharmaceutical made up 0.01% of Arrowstreet Capital's portfolio in Q1 2026, its #705 holding.
  • Arrowstreet Capital first reported a position in Catalyst Pharmaceutical in Q4 2019 and has held it in 18 quarters since.
  • Arrowstreet Capital's Catalyst Pharmaceutical position peaked at $37.7M in Q4 2025.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Arrowstreet Capital's 13F filing for Q1 2026, filed 14 May 2026.